EGFR Inhibitor HM61713

Known as: HM61713 
An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
024620142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
EGFR T790M mutation leads to resistance to most of clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M… (More)
Is this relevant?
Review
2017
Review
2017
PURPOSE OF REVIEW The most common mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors… (More)
  • figure 1
Is this relevant?
2016
2016
T790M mutation is most common resistant mechanism to epidermal growth factor receptor gene (EGFR) tyrosin kinase inhibitor (TKI… (More)
Is this relevant?
2016
2016
effusion. There were 410 male and 120 female, with a mean age of 54 years. In 401 patients VATS was performed under general… (More)
Is this relevant?
Review
2016
Review
2016
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2016
Review
2016
Since the discovery of sensitizing EGFR mutations as a predictive marker of sensitivity to EGFR tyrosine kinase inhibitors (TKIs… (More)
  • table 2
  • table 3
  • table 3
  • figure 1
  • table 4
Is this relevant?
Review
2016
Review
2016
PURPOSE OF REVIEW Patients with epidermal growth factor receptor (EGFR) mutation-positive nonsmall cell lung cancer (NSCLC… (More)
Is this relevant?
Review
2015
Review
2015
EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line treatment for non-small-cell lung… (More)
  • table 1
  • table 2
  • table 4
  • table 5
  • figure 1
Is this relevant?